Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
Did you know that India is one of the most linguistically diverse countries in the…
Recently unveiled The top 10 youngest billionaires 2026 list highlights the new generation of wealth…
The number of self-made women billionaires worldwide has reached a record 150 in 2026. This…
India and Vietnam have strengthened the cooperation in tribal and ethnic development. This coming after…
Did you know that salt is one of the most essential minerals used by humans…
The World Anti-Doping Agency (WADA) has postponed its decision on to a proposed rule that…